Equity research analysts covering BioXcel Therapeutics maintain varied 12-month consensus price targets that reflect the high-risk, high-reward nature of clinical-stage biotechnology equities. Target valuations depend heavily on upcoming clinical trial readouts for its neuroscience and agitation drug pipelines, regulatory milestone updates, and active capital-restructuring strategies evaluated across small-cap healthcare markets.